Human Insulin NPH and Insulin Aspart in Type 1 Diabetes

Novo Nordisk A/S91 enrolled

Overview

This trial is conducted in South America. This aim of this trial is to evaluate the comparative prandial blood glucose lowering profile in subjects with type 1 diabetes.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Diabetes Diabetes Mellitus, Type 1

Interventions

insulin aspartDRUG

soluble human insulinDRUG

insulin NPHDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Type 1 diabetes for at least 12 months * Treatment with insulin NPH * Body Mass Index (BMI) below 30 kg/m2 Exclusion Criteria: * Total daily insulin dose greater than 1.40 IU/kg * Treatment with oral antidiabetic drugs (OADs)

Locations (1)

Novo Nordisk Investigational Site

Junín, Argentina

Outcomes

Primary Outcomes

Prandial blood glucose lowering profile

Time frame: between 1st and 2nd post prandial hours

Secondary Outcomes

Hypoglycaemic events

Adverse events

Serious adverse events

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.